Fluoroquinolone Prophylaxis for Neutropenic HSCT Recipients: At What Cost?

While decreasing the incidence of bacterial infections in hematopoietic stem-cell transplant recipients, this practice may have caused a shift to infections caused by more-resistant organisms.

The introduction of fluoroquinolone prophylaxis in 2005 has dramatically changed the management of individuals with neutropenic fever. To examine changes in the epidemiology of microbes in this patient population, investigators retrospectively evaluated microbial isolates from all 586 adults who underwent hematopoietic stem-cell transplantation (HSCT) at one center in Australia between 2001 and 2010. Antimicrobial prophylaxis and treatment of neutropenic fever were provided in accordance with published guidelines.

Despite a growing frequency of transplants over the study period, the number of positive cultures decreased, with the most dramatic drop occurring between 2001–2004 and 2004–2007. Enterococcal species (particularly Enterococcus fae…

Reviewing Author

Sonia Nagy Chimienti, MD

Disclosures

Nothing to disclose

Sonia Nagy Chimienti, MD

Disclosures

Nothing to disclose

Fluoroquinolone Prophylaxis for Neutropenic HSCT Recipients: At What Cost?

Topics

Reviewing Author